Abstract |
Imipenem/cilastatin is highly effective for infections in many body sites against a broad range of gram-positive and gram-negative aerobic and anaerobic bacteria. During therapy, development of resistance is uncommon except in the case of Pseudomonas aeruginosa in which the incidence appears similar to that for other beta-lactam antibiotics. There appears to be a very low probability of cross-resistance. The clinical and laboratory adverse reactions are similar in type to those for other beta-lactam antibiotics. The frequency of colonization and superinfection during treatment with imipenem/cilastatin has been comparable to other antibiotics in comparative trials and to literature reports for other antibiotics for noncomparative trials.
|
Authors | G B Calandra, F M Ricci, C Wang, K R Brown |
Journal | Journal of clinical pharmacology
(J Clin Pharmacol)
Vol. 28
Issue 2
Pg. 120-7
(Feb 1988)
ISSN: 0091-2700 [Print] England |
PMID | 3283176
(Publication Type: Journal Article, Review)
|
Chemical References |
- Cyclopropanes
- Thienamycins
- Cilastatin
- Imipenem
|
Topics |
- Bacterial Infections
(drug therapy, microbiology)
- Cilastatin
- Cyclopropanes
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Imipenem
- Thienamycins
(administration & dosage, adverse effects, therapeutic use)
|